Canakinumab

BNF:
8.2.4
Status:
Do Not Prescribe (DNP)
Decision Date:
None
 

Comments

Do Not Prescribe (DNP): 

  • NICE TA281: for treating gouty arthritis attacks and reducing the frequency of subsequent attacks.  (Terminated appraisal).  (Decision date - May 2013).
  • NICE TA302: for treating systemic juvenile idiopathic arthritis.  (Decision date - December 2013).
  • NHSE Clinical Commissioning Policy SSC2437: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)- The policy confirms that canakinumab is not routinely commissioned for these patients. (Decision date - November 2022).

Black Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

search again